key: cord-0992411-ri4rkr4e
authors: Sookaromdee, Pathum; Wiwanitkit, Viroj
title: Adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine
date: 2021-11-24
journal: Med J Armed Forces India
DOI: 10.1016/j.mjafi.2021.10.012
sha: e3ec07a8d07ca343ada8b38424efd3b818676b9f
doc_id: 992411
cord_uid: ri4rkr4e

nan

Correspondence/Letter to the Editor Adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine Dear Editor,

We would like to share ideas on "Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers". 1 Adverse event after vaccination is an interesting issue at present. The difference in the incidence of AEFI among ones with and without previous COVID might be due to many reasons. A possible explanation is on the immune response. In a recent report, the immune response in ones with previous COVID-19 is higher, and it results in a higher blood viscosity, which might result in AEFI. 2 It is necessary for good history taking for previous COVID-19 before vaccination, and there should be a good monitoring of post vaccination for those with previous COVID-19. r e f e r e n c e s Authors reply to 'Adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine' No evidence to prove association of COVID vaccine with blood hyperviscosity Dear Editor, Our study 1 has reported higher incidence of mild adverse events following immunisation (AEFI) after first dose of COVID vaccine among previously infected health care workers. These mild AEFI reported were due to vaccine reactogenicity mediated by cytokines. The clinical symptoms commonly associated with hyperviscosity i.e. neurological symptoms, visual symptoms and thrombosis were not observed in our study. Though research studies 2-3 have documented higher antibody levels after COVID vaccination among previously infected individuals, its association with greater viscosity of blood as suggested by Joob B et al 4 , is not proven by any empirical study yet. Moreover, no study has reported higher risk of serious AEFI after vaccination among COVID recovered individuals. 3, [5] [6] No other vaccine has been found to be associated with hyperviscosity syndrome till date. Hence, we cannot infer that individuals with previous COVID infection are at a greater risk of developing higher blood viscosity or other serious AEFI after COVID vaccination. r e f e r e n c e s

Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers

Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv

Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Vaccine after effects more common in those who already, had COVID

Patients with history of COVID-19 had more side effects after the first dose of covid-19 vaccine. Vaccine